New Topics in Vasopressin Receptors and Approach to Novel Drugs: Vasopressin and Pain Perception
New Topics in Vasopressin Receptors and Approach to Novel Drugs: Vasopressin and Pain Perception
复制标题
DOI：
10.1254/jphs.08r18fm
复制
发表时间：
2009-01-01
影响因子：
3.5
通讯作者：
Tsujimoto, Gozoh
中科院分区：
文献类型：
--
作者：
Koshimizu, Taka-aki;Tsujimoto, Gozoh
精氨酸抗利尿激素（AVP）激活三种抗利尿激素受体，并对催产素受体具有激动作用。为了准确描述负责复杂AVP和催产素作用的靶受体亚型，需要仔细评估配体特异性和受体活性，特别是当这些受体在中枢神经系统中共表达时。先前的研究表明，AVP通过直接激活中枢抗利尿激素受体和位于外周组织的受体，在伤害感觉中起调节作用。基因改变的啮齿动物模型，包括AVP缺陷突变的Brattleboro大鼠和缺乏内源性阿片肽的基因敲除小鼠，促进了对疼痛感知过程和AVP系统之间相互作用的理解。本报告回顾了这一重要领域的先前研究结果，并将其与最近的基因敲除/敲低研究结果进行了比较。
Arginine vasopressin (AVP) activates three vasopressin receptors and it also has an agonistic activity on the oxytocin receptor. For ail accurate description of the target receptor subtype(s) responsible for complex AVP and oxytocin actions, a careful evaluation of ligand specificity and receptor activities are required, particularly when these receptors are co-expressed in the central nervous system. Previous studies suggest that AVP plays a regulatory role in nociception through the direct activation of central vasopressin receptors and also through the receptors that reside in the peripheral tissues. Genetically altered rodent models, including the AVP-deficient Mutant Brattleboro rat and gene knockout mice lacking an endogenous opioid peptide, advanced the understanding of the interactions between the pain perception process and AVP system. This report reviews previous findings in this important field and reconciles them with the findings of recent gene knockout/knockdown Studies.